Daré Bioscience, Inc.
DARE
$1.95
$0.105.14%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 4,368.34% | 10,412.24% | -103.04% | -100.62% | -99.08% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4,368.34% | 10,412.24% | -103.04% | -100.62% | -99.08% |
| Cost of Revenue | 57.86% | 77.04% | -127.18% | -124.04% | -124.01% |
| Gross Profit | -38.83% | -56.24% | 128.95% | 127.05% | 127.18% |
| SG&A Expenses | -1.04% | -4.29% | -9.22% | -18.99% | -21.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -40.43% | -37.84% | -30.12% | -37.61% | -29.36% |
| Operating Income | 45.62% | 42.21% | 24.16% | 30.92% | 22.44% |
| Income Before Tax | -617.02% | -230.55% | -384.47% | -158.33% | 94.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -617.02% | -230.55% | -384.47% | -158.33% | 94.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -617.02% | -230.55% | -384.47% | -158.33% | 94.19% |
| EBIT | 45.62% | 42.21% | 24.16% | 30.92% | 22.44% |
| EBITDA | 54.41% | 49.16% | 28.90% | 33.24% | 23.07% |
| EPS Basic | -413.13% | -161.76% | -271.97% | -106.91% | 94.68% |
| Normalized Basic EPS | -412.87% | -161.65% | -292.79% | -112.41% | 94.64% |
| EPS Diluted | -417.69% | -172.21% | -259.64% | -103.59% | 94.22% |
| Normalized Diluted EPS | -384.93% | -155.79% | -283.62% | -110.03% | 94.33% |
| Average Basic Shares Outstanding | 49.55% | 33.98% | 17.74% | 7.94% | 10.72% |
| Average Diluted Shares Outstanding | 49.26% | 33.72% | 17.51% | 7.71% | 10.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |